MARGERY H MARK, MD
Neurology at Paterson St, New Brunswick, NJ
License number
New Jersey 25MA04805800
Category
Neurology
Type
Neurology
Address
Address
2
125 Paterson St SUITE 6100, New Brunswick, NJ 08901
66 W Gilbert St FLOOR 2ND, Tinton Falls, NJ 07701
66 W Gilbert St FLOOR 2ND, Tinton Falls, NJ 07701
Phone
(732) 235-7733
(732) 235-7041 (Fax)
(732) 212-0051
(732) 212-0713 (Fax)
(732) 235-7041 (Fax)
(732) 212-0051
(732) 212-0713 (Fax)
Personal information
See more information about MARGERY H MARK at radaris.comName
Address
Phone
900 Princeton Kingston Rd, Princeton, NJ 08540
1 Robert Wood Johnson Pl, New Brunswick, NJ 08901
900 Kingston Ter, Princeton, NJ 08540
900 Princeton Kingston Rd, Princeton, NJ 08540
Organization information
See more information about MARGERY H MARK at bizstanding.comMargery H Mark MD
1 Robert Wood Johnson Pl, New Brunswick, NJ 08901
Industry:
Medical Doctor's Office
Principals:
Margery H. Mark (Medical Doctor),Jerry Belsh (Principal)
Professional information
See more information about MARGERY H MARK at trustoria.com
Margery H Mark, New Brunswick NJ
Margery H Mark, New Brunswick NJ
Specialties:
Neurologist
Address:
125 Paterson St, New Brunswick, NJ 08901
Education:
State University of New York Downstate Medical Center, College of Medicine - Doctor of Medicine
Bristol-Myers Squibb Children's Hospital - Fellowship - Movement Disorders
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Neurology
Bristol-Myers Squibb Children's Hospital - Fellowship - Movement Disorders
New York Presbyterian Hospital-Columbia Presbyterian Center - Residency - Neurology
Board certifications:
American Board of Psychiatry and Neurology Certification in Neurology (Psychiatry and Neurology)
Dr. Margery H Mark, New Brunswick NJ - MD (Doctor of Medicine)
Dr. Margery H Mark, New Brunswick NJ - MD (Doctor of Medicine)
Specialties:
Neurology, Neuropsychiatry (Neurology)
Address:
Robert Wood Johnson Medical Group-Neurology
125 Paterson St SUITE 6100, New Brunswick 08901
(732) 828-3000 (Phone), (732) 235-7041 (Fax)
125 Paterson St SUITE 6100, New Brunswick 08901
(732) 828-3000 (Phone), (732) 235-7041 (Fax)
Certifications:
Neurology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English, Chinese, Spanish
Hospitals:
Robert Wood Johnson Medical Group-Neurology
125 Paterson St SUITE 6100, New Brunswick 08901
Robert Wood Johnson University Hospital
1 Robert Wood Johnson Pl, New Brunswick 08903
125 Paterson St SUITE 6100, New Brunswick 08901
Robert Wood Johnson University Hospital
1 Robert Wood Johnson Pl, New Brunswick 08903
Education:
Medical School
SUNY Downstate Medical Center College Of Medicine
Graduated: 1982
Staten Island Hospital
Graduated: 1983
Neur Inst/Colum Presby Med
Graduated: 1986
UMDNJ Rw Johnson Med School
Graduated: 1987
SUNY Downstate Medical Center College Of Medicine
Graduated: 1982
Staten Island Hospital
Graduated: 1983
Neur Inst/Colum Presby Med
Graduated: 1986
UMDNJ Rw Johnson Med School
Graduated: 1987
Margery Hope Mark, New Brunswick NJ
Margery Hope Mark, New Brunswick NJ
Specialties:
Neurology, Nephrology
Work:
Robert Wood Johnson Univ Hosp
97 Paterson St, New Brunswick, NJ 08901
97 Paterson St, New Brunswick, NJ 08901
Education:
State University of New York Downstate (1982)
Pharmaceutical Compositions And Method Of Treating Parkinson's Disease
Pharmaceutical Compositions And Method Of Treating Parkinson's Disease
US Patent:
2006015, Jul 13, 2006
Filed:
Dec 19, 2003
Appl. No.:
10/539872
Inventors:
Nancy Hathaway - Woodbridge NJ, US
Margery Mark - New Brunswick NJ, US
Margery Mark - New Brunswick NJ, US
International Classification:
A61K 31/498, A61K 31/48, A61K 31/137, A61K 31/44, A61K 31/415, A61K 31/366
US Classification:
514250000, 514406000, 514284000, 514424000, 514471000, 514649000, 514663000
Abstract:
This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, this invention is directed to pharmaceutical compositions for treating and methods of treating Parkinson s disease comprising the use of selective cyclooxygenase-2 inhibitors, such as rofecoxib, etoricoxib, celecoxib and valdecoxib, with and without concomitant use of one or more antiparkinson drugs.